Quest Diagnostics, Inc.

Quest Diagnostics, Inc.

DGX

Get informed when a big investor buys or sells

+ Follow
Market Cap$25.72B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Quest Diagnostics, Inc.Quest Diagnostics, Inc.24.41.42%14%2.20.8

Earnings Call Q2 2026

July 23, 2026 - AI Summary

Q2 performance: strong top + bottom line (and broad demand) - Revenues: $3.04B, +10.2% YoY (reported), with organic revenue up 10%. - EPS: Reported diluted EPS $2.84 (+14.9% YoY); Adjusted diluted EPS $3.12 (+19.1% YoY). - Volume: Requisitions +13.1% YoY (organic volume +13%); Corewell + Fresenius contributed ~9% of volume. - Revenue per requisition: -2.8% YoY due to Corewell/Fresenius mix, but +2.9% YoY excluding mix, driven mainly by more tests per requisition; unit price reimbursement ~flat.
Guidance raised for full-year 2026 (key forecast numbers) - Revenue: now $11.95B–$12.05B (implies 8.3% to 9.2% growth, excluding any prospective M&A contribution). - EPS: Reported EPS $9.97–$10.17; Adjusted EPS $11.05–$11.25. - Cash flow & capex: Cash from operations ~ $1.8B; Capex ~ $550M. - Why the raise: continued momentum across physician, hospital, and consumer channels plus ongoing gains from automation/AI and “Invigorate” cost program.
Second-half outlook: margin headwinds but expected full-year expansion - Q2 operating margin (adjusted): 16.5%, down ~40 bps YoY due to: - Nova/project investment (~20 bps), - Corewell + Fresenius ramp/mix (~30 bps), - SDCP supplemental deferred comp mark-to-market (~20 bps). - Second-half margin drivers: - Fuel costs expected to be toward the high end previously guided (roughly ~$10M impact). - Nova spend timing: now expected ~70% of full-year in 2H (previously ~60%). - Offset: volume strength + lapse/less dilution from Corewell/Fresenius starting in Q4 → still expect operating margin expansion vs prior year for full year.

Exclusive for Stockcircle Pro members

Sign upSign Up
$237.56

Target Price by Analysts

1.6% upsideQuest Diagnostics Target Price DetailsTarget Price
$209.70

Current Fair Value

10.3% downside

Overvalued by 10.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$25.72 Billion
Enterprise Value$31.48 Billion
Dividend Yield$3.32 (1.42%)
Earnings per Share$8.87
Beta0.57
Outstanding Shares110,000,000

Return

Return on Equity14.13%ROE
Return on Assets6.27%
Return on Invested Capital10.83%

Valuation & Multiples

P/E Ratio24.42P/E Ratio
PEG175.98PEG
Price to Sales2.23Price to Sales
Price to Book Ratio3.29Price to Book Ratio
Enterprise Value to Revenue2.72
Enterprise Value to EBIT19.18
Enterprise Value to Net Income29
Total Debt to Enterprise0.2
Debt to Equity0.85Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 28, 2026
EPS Estimate
$2.81
Average shareholder expectation
Revenue Estimate
$2.98 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 20, 2026
EPS Estimate
$2.85
Average shareholder expectation
Revenue Estimate
$3.04 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 40.52%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %5.07%▼ 87.31%
Total Invested$1.18B▼ 94.15%
Investors Holding444▼ 633.00%

ESG Score

No data

About Quest Diagnostics, Inc.

47,000 employees
CEO: Stephen Rusckowski

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy beh...

Relevant Senate Committees

Finance

As the primary committee for taxation, trade, and entitlement spending, it directly impacts Quest Diagnostics through corporate tax policy and, critically, by influencing Medicare/Medicaid reimbursement rates, which are major revenue drivers for clinical laboratories.

Appropriations

This committee directly allocates federal discretionary spending. Its subcommittees determine funding for various healthcare programs (Medicare, Medicaid, VA) which provide significant revenue to Quest Diagnostics for its services, making it a critical source of financial influence.

Health, Education, Labor, and Pensions

This committee directly regulates key aspects of Quest Diagnostics' business, including FDA oversight of diagnostic tests (IVDs), NIH funding for health research, and labor laws affecting its 47,000 employees. Changes in these areas directly impact DGX's operations and costs.

Veterans' Affairs

Quest Diagnostics likely serves veterans through the Department of Veterans Affairs or related programs. This committee's funding decisions directly impact government healthcare contractors and the delivery of healthcare services to veterans, a significant client base for Quest Diagnostics.